Malaria vaccine CDC/NIIMALVAC-1

Drug Profile

Malaria vaccine CDC/NIIMALVAC-1

Alternative Names: CDC/NIIMALVAC-1; Malaria vaccine multistage and multivalent

Latest Information Update: 29 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 19 Jul 2000 A preclinical study has been added to the Parasitic Infections immunogenicity section
  • 19 Feb 1999 New profile
  • 19 Feb 1999 Preclinical development for Malaria in India (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top